Skip to main content

 Scientific publications

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.

Authors : Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P
Year : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 1124-1135

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Authors : Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG
Year : 2019
Journal : Future Oncol
Volume : 15
Pages : 3209-3218

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Authors : Pondé N, Aftimos P, Piccart-Gebhart M
Year : 2019
Journal : Curr Treat Options Oncol
Volume : 20
Pages : 37

Lucitanib for the treatment of HR<sup>+</sup>/ HER2<sup>-</sup> metastatic breast cancer: results from the multicohort phase II FINESSE study.

Authors : Hui R, Pearson A, Cortés J, Campbell C, Poirot C, Azim HA, Fumagalli D, Lambertini M, Daly F, Arahmani A, Pérez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G
Year : 2019
Journal : Clin Cancer Res

Extended time interval between diagnosis and surgery does not improve the outcome in patients operated for resection or ablation of breast cancer liver metastases.

Authors : Lucidi V, Bohlok A, Liberale G, Bez M, Germanova D, Bouazza F, Demetter P, Larsimont D, Aftimos P, Smoll NR, Donckier V
Year : 2019
Journal : Eur J Surg Oncol

Celyad's novel CAR T-cell therapy for solid malignancies.

Authors : Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels JH, Van den Eynde M, Canon JL, Carrasco J, Odunsi K, Sahebjam S, Rottey S, Braun N, Verma B, Gilham DE, Lehmann FF
Year : 2018
Journal : Curr Res Transl Med
Volume : 66(2)
Pages : 53-56

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Authors : Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos P, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C
Year : 2018
Journal : J Clin Oncol
Volume : 36
Pages : 3007-3014

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.

Authors : Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart-Gebhart M, Rothé F, Sotiriou C
Year : 2018
Journal : Ann Oncol
Volume : 29(4)
Pages : 895-902

Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.

Authors : Maurer C, Ferreira AR, Martel S, Lambertini M, Pondé N, Aftimos P, de Azambuja E, Piccart-Gebhart M
Year : 2018
Journal : Breast
Volume : 39
Pages : 14-18

Network science in clinical trials: A patient-centered approach.

Authors : Manem VSK, Salgado R, Aftimos P, Sotiriou C, Haibe-Kains B
Year : 2018
Journal : Semin Cancer Biol
Volume : 52
Pages : 135-150

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Authors : Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A
Year : 2017
Journal : Clin Cancer Res
Volume : 23(21)
Pages : 6411-6420

Adenoid cystic carcinoma of the breast - an aggressive presentation with pulmonary, kidney, and brain metastases: a case report.

Authors : Mhamdi HA, Kourie HR, Jungels C, Aftimos P, Belbaraka R, Piccart-Gebhart M
Year : 2017
Journal : J Med Case Rep
Volume : 11
Pages : 303

Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer.

Authors : Kourie HR, Mavroudakis N, Aftimos P, Piccart-Gebhart M
Year : 2017
Journal : World J Clin Oncol
Volume : 8
Pages : 425-428

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.

Authors : Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF
Year : 2017
Journal : BMJ Open
Volume : 7(11)
Pages : e017075

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Authors : Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G
Year : 2017
Journal : Oncotarget
Volume : 8(2)
Pages : 2320-2328

The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group.

Authors : Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, Loibl S, Laes JF, Campbell PJ, Thompson A, Cortes J, Seiler S, Vinnicombe S, Oliveira M, Rothé F, Bareche Y, Fumagalli D, Zardavas D, Desmedt C, Piccart-Gebhart M, Loi S, Sotiriou C
Year : 2017
Journal : NPJ Breast Cancer
Volume : 3
Pages : 23

Emerging Drugs Targeting Human Epidermal Growth Factor Receptor 2 (Her2) In The Treatment Of Breast Cancer.

Authors : Awada G, Gombos A, Aftimos P, Awada A
Year : 2016
Journal : Expert Opin Emerg Drugs
Volume : 21(1)
Pages : 91-101

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Authors : Awada A, Campone M, Varga A, Aftimos P, Frenel JS, Bahleda R, Gombos A, Bourbouloux E, Soria JC
Year : 2016
Journal : Anticancer Drugs
Volume : 27(4)
Pages : 342-8

The current use and attitudes towards tumor genome sequencing in breast cancer.

Authors : Gingras I, Sonnenblick A, de Azambuja E, Paesmans M, Delaloge S, Aftimos P, Piccart-Gebhart M, Sotiriou C, Ignatiadis M, Azim HA Jr
Year : 2016
Journal : Sci Rep
Volume : 6
Pages : 22517

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Authors : Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A
Year : 2016
Journal : Eur J Cancer
Volume : 60
Pages : 117-124